Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1629 1691
This examiner grants 76% of resolved cases
D. Margaret M. Seaman is an examiner in Tech Center 1600 and Art Unit 1625. She has 1405 resolved cases. The allowance rate for these cases is 76.5 percent. This figure indicates the proportion of applications that result in a patent grant within her docket. This 76.5 percent rate is a recorded outcome for the 1405 cases resolved in Tech Center 1600.
The interview lift is 8.0 percent. This 8.0 percent lift shows the increase in allowance probability when an interview is conducted. The median days to allowance is 799. This timeline provides a median expectation for the duration of successful prosecution. The 799-day median pendency is a key metric for applicants in Art Unit 1625.
Practitioners can use the 1405 resolved cases to evaluate the consistency of these metrics. The 76.5 percent allowance rate is a factor for strategy. The 799-day median pendency and the 8.0 percent lift offer a data-grounded view of the prosecution process for this examiner. These figures provide a basis for evaluating the impact of direct communication on the 76.5 percent baseline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18825507 | Organic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | Non-Final OA | Semiconductor Energy Laboratory Co., Ltd. |
| 17998911 | METHODS FOR THE TREATMENT OF PANCREATITIS AND PREVENTION OF PANCREATIC CANCER | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18829953 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18864247 | ANTIBIOTIC COMPOSITION AND METHODS OF USE THEREOF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE |
| 17962656 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | Final Rejection | The Regents of the University of Colorado, a body corporate |
| 18277623 | BORON NEUTRON CAPTURE THERAPY (BNCT) PROBE | Non-Final OA | The University of Tokyo |
| 18865274 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18557651 | METHODS OF TREATING CANCER AND ISCHEMIA DISEASES BY INHIBITION AND INTERVENTION OF ATR PROLYL ISOMERIZATION | Final Rejection | The University of Toledo |
| 18908611 | POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | Non-Final OA | CORCEPT THERAPEUTICS INCORPORATED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy